BioXcel Therapeutics
BTAI
104 hedge funds and large institutions have $431M invested in BioXcel Therapeutics in 2020 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 10 closing their positions.
340% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 10
269% more capital invested
Capital invested by funds: $117M → $431M (+$314M)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
110% more call options, than puts
Call options by funds: $27.9M | Put options by funds: $13.3M
70% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 20
49% more funds holding
Funds holding: 70 → 104 (+34)
0.65% more ownership
Funds ownership: 1.86% → 2.51% (+0.65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$34.6M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$20.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12.8M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$12.2M |
| 5 |
BlackRock
New York
|
+$9.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.9M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$17.3M |
| 3 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$3.48M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$3.23M |
| 5 |
MAP
Moody Aldrich Partners
Marblehead,
Massachusetts
|
-$2.46M |
BTAI Hedge Fund Activity: Q2 2020 in Review
104 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2020, worth a combined $431M — up 269% from $117M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new BTAI positions and 10 closed out — a net gain of 34 holders — while 34 added to existing stakes and 20 trimmed.
The largest buyer was State Street, adding an estimated $34.6M. The largest seller was Fidelity Investments, cutting an estimated $17.9M.
- 104 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2020, up from 70 in Q1 2020.
- Funds reported $431M of BioXcel Therapeutics stock for Q2 2020, up 269% quarter-over-quarter.
- 44 funds opened new BioXcel Therapeutics positions in Q2 2020 and 10 closed out, a net change of +34 holders.
- The largest BioXcel Therapeutics buyer in Q2 2020 was State Street, an estimated $34.6M added.
- The largest BioXcel Therapeutics seller in Q2 2020 was Fidelity Investments, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2020.